The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01B | Antiarrhythmics, class I and III | |
| 4 | C01BC | Antiarrhythmics, class Ic | |
| 5 | C01BC03 | Propafenone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.3 g |
| PAREN - Parenteral | 0.3 g |
| Active Ingredient | Description | |
|---|---|---|
| Propafenone |
Propafenone is a class IC anti-arrhythmic agent. It has a stabilising action on myocardial membranes, reduces the fast inward current carried by sodium ions with a reduction in depolarisation rate and prolongs the impulse conduction time in the atrium, AV node and primarily, in the His-Purkinje system. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ARYTHMOL Film coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| RYTHMOL SR Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RYTMONORM Film-coated tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
